{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T20:16:27Z","timestamp":1781813787470,"version":"3.54.5"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s41030-025-00323-0","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:00:26Z","timestamp":1764583226000},"page":"57-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Misconceptions of Traits to Predict Response to Inhaled Corticosteroid and Bronchodilator Therapies in Asthma: A Narrative Review"],"prefix":"10.1007","volume":"12","author":[{"given":"Guy","family":"Brusselle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Leather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Oppenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Stanaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Pizzichini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"323_CR1","unstructured":"Global Initiative for Asthma. Global Initative for Asthma: Global Strategy for Asthma Management and Prevention. 2025. Available from: https:\/\/ginasthma.org\/2025-gina-strategy-report\/. Accessed May 2025."},{"issue":"1068\u201374","key":"323_CR2","volume":"132","author":"SP Peters","year":"2013","unstructured":"Peters SP, Bleecker ER, Kunselman SJ, et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults. J Allergy Clin Immunol. 2013;132(1068\u201374):e1.","journal-title":"J Allergy Clin Immunol"},{"key":"323_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1067\/mai.2002.122635","volume":"109","author":"SJ Szefler","year":"2002","unstructured":"Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109:410\u20138.","journal-title":"J Allergy Clin Immunol"},{"key":"323_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.rmed.2019.09.014","volume":"158","author":"TB Casale","year":"2019","unstructured":"Casale TB, Aalbers R, Bleecker ER, et al. Tiotropium Respimat(R) add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics. Respir Med. 2019;158:97\u2013109.","journal-title":"Respir Med"},{"key":"323_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaci.2006.10.035","volume":"119","author":"RJ Martin","year":"2007","unstructured":"Martin RJ, Szefler SJ, King TS, et al. The predicting response to inhaled corticosteroid efficacy (PRICE) trial. J Allergy Clin Immunol. 2007;119:73\u201380.","journal-title":"J Allergy Clin Immunol"},{"key":"323_CR6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00561-2019","author":"C Janson","year":"2019","unstructured":"Janson C, Malinovschi A, Amaral AFS, et al. Bronchodilator reversibility in asthma and COPD: findings from three large population studies. Eur Respir J. 2019. https:\/\/doi.org\/10.1183\/13993003.00561-2019.","journal-title":"Eur Respir J"},{"key":"323_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12931-021-01767-z","volume":"22","author":"C Lemiere","year":"2021","unstructured":"Lemiere C, Taille C, Lee JK, et al. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two phase III trials. Respir Res. 2021;22:184.","journal-title":"Respir Res"},{"key":"323_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.alit.2017.02.013","volume":"66","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Uno T, Sato H, et al. Predicting future risk of exacerbations in Japanese patients with adult asthma: a prospective 1-year follow up study. Allergol Int. 2017;66:568\u201373.","journal-title":"Allergol Int"},{"key":"323_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12931-021-01864-z","volume":"22","author":"OD Tupper","year":"2021","unstructured":"Tupper OD, Ulrik CS. Long-term predictors of severe exacerbations and mortality in a cohort of well-characterised adults with asthma. Respir Res. 2021;22:269.","journal-title":"Respir Res"},{"key":"323_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","volume":"391","author":"ID Pavord","year":"2018","unstructured":"Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet. 2018;391:350\u2013400.","journal-title":"Lancet"},{"key":"323_CR11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00936-2018","author":"ER Bleecker","year":"2018","unstructured":"Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018. https:\/\/doi.org\/10.1183\/13993003.00936-2018.","journal-title":"Eur Respir J"},{"key":"323_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pupt.2017.01.011","volume":"43","author":"G Brusselle","year":"2017","unstructured":"Brusselle G, Germinaro M, Weiss S, Zangrilli J. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther. 2017;43:39\u201345.","journal-title":"Pulm Pharmacol Ther"},{"key":"323_CR13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04605-2020","author":"WW Busse","year":"2021","unstructured":"Busse WW, Paggiaro P, Mu\u00f1oz X, et al. Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. Eur Respir J. 2021. https:\/\/doi.org\/10.1183\/13993003.04605-2020.","journal-title":"Eur Respir J"},{"key":"323_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.01.025","author":"B Geng","year":"2022","unstructured":"Geng B, Dixon AE, Ko J, et al. Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol. 2022. https:\/\/doi.org\/10.1016\/j.anai.2022.01.025.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"323_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","volume":"386","author":"GG Brusselle","year":"2022","unstructured":"Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386:157\u201371.","journal-title":"N Engl J Med"},{"key":"323_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113978","volume":"179","author":"JA Kroes","year":"2020","unstructured":"Kroes JA, Zielhuis SW, van Roon EN, Ten Brinke A. Prediction of response to biological treatment with monoclonal antibodies in severe asthma. Biochem Pharmacol. 2020;179:113978.","journal-title":"Biochem Pharmacol"},{"key":"323_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","volume":"197","author":"M Mukherjee","year":"2018","unstructured":"Mukherjee M, Paramo FA, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med. 2018;197:38\u201346.","journal-title":"Am J Respir Crit Care Med"},{"key":"323_CR18","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1164\/rccm.201910-1934CI","volume":"201","author":"R Beasley","year":"2020","unstructured":"Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Pavord ID. Optimal asthma control: time for a new target. Am J Respir Crit Care Med. 2020;201:1480\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"323_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/cea.13829","volume":"52","author":"A Edris","year":"2022","unstructured":"Edris A, de Roos EW, McGeachie MJ, et al. Pharmacogenetics of inhaled corticosteroids and exacerbation risk in adults with asthma. Clin Exp Allergy. 2022;52:33\u201345.","journal-title":"Clin Exp Allergy"},{"key":"323_CR20","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/S0140-6736(09)61492-6","volume":"374","author":"ME Wechsler","year":"2009","unstructured":"Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet. 2009;374:1754\u201364.","journal-title":"Lancet"},{"key":"323_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.anai.2020.12.015","volume":"126","author":"J Oppenheimer","year":"2021","unstructured":"Oppenheimer J, Slade DJ, Hahn BA, et al. Real-world evidence: Patient views on asthma in respiratory specialist clinics in America. Ann Allergy Asthma Immunol. 2021;126:385\u2013932.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"323_CR22","doi-asserted-by":"crossref","unstructured":"Nwaru BI, Ekstrom M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020; 55.","DOI":"10.1183\/13993003.01872-2019"},{"key":"323_CR23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1513\/pats.200409-045MS","volume":"1","author":"PJ Barnes","year":"2004","unstructured":"Barnes PJ. Distribution of receptor targets in the lung. Proc Am Thorac Soc. 2004;1:345\u201351.","journal-title":"Proc Am Thorac Soc"},{"key":"323_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejim.2021.01.027","volume":"85","author":"A Papi","year":"2021","unstructured":"Papi A, Fabbri LM, Kerstjens HAM, Rogliani P, Watz H, Singh D. Inhaled long-acting muscarinic antagonists in asthma - a narrative review. Eur J Intern Med. 2021;85:14\u201322.","journal-title":"Eur J Intern Med"},{"key":"323_CR25","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","volume":"394","author":"JC Virchow","year":"2019","unstructured":"Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394:1737\u201349.","journal-title":"Lancet"},{"key":"323_CR26","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S2213-2600(20)30190-9","volume":"8","author":"HAM Kerstjens","year":"2020","unstructured":"Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8:1000\u201312.","journal-title":"Lancet Respir Med"},{"key":"323_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","volume":"9","author":"LA Lee","year":"2021","unstructured":"Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9:69\u201384.","journal-title":"Lancet Respir Med"},{"key":"323_CR28","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1001\/jama.2021.7872","volume":"325","author":"LHY Kim","year":"2021","unstructured":"Kim LHY, Saleh C, Whalen-Browne A, O\u2019Byrne PM, Chu DK. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis. JAMA. 2021;325:2466\u201379.","journal-title":"JAMA"},{"key":"323_CR29","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1002\/sim.1815","volume":"23","author":"P Royston","year":"2004","unstructured":"Royston P, Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med. 2004;23:2509\u201325.","journal-title":"Stat Med"},{"key":"323_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2307\/2986270","volume":"43","author":"P Royston","year":"1994","unstructured":"Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. Appl Stat. 1994;43:429\u201353.","journal-title":"Appl Stat"},{"key":"323_CR31","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","volume":"332","author":"DG Altman","year":"2006","unstructured":"Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332:1080.","journal-title":"BMJ"},{"key":"323_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/sim.2331","volume":"25","author":"P Royston","year":"2006","unstructured":"Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25:127\u201341.","journal-title":"Stat Med"},{"key":"323_CR33","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03393-2020","author":"WW Busse","year":"2021","unstructured":"Busse WW, Kraft M, Rabe KF, et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J. 2021. https:\/\/doi.org\/10.1183\/13993003.03393-2020.","journal-title":"Eur Respir J"},{"key":"323_CR34","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","volume":"3","author":"DB Price","year":"2015","unstructured":"Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3:849\u201358.","journal-title":"Lancet Respir Med"},{"key":"323_CR35","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00570-2021","author":"S Couillard","year":"2022","unstructured":"Couillard S, Do WIH, Beasley R, Hinks TSC, Pavord ID. Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE). ERJ Open Res. 2022. https:\/\/doi.org\/10.1183\/23120541.00570-2021.","journal-title":"ERJ Open Res"},{"key":"323_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.anai.2020.04.025","volume":"125","author":"HI Rhyou","year":"2020","unstructured":"Rhyou HI, Nam YH. Predictive factors of response to inhaled corticosteroids in newly diagnosed asthma: a real-world observational study. Ann Allergy Asthma Immunol. 2020;125:177\u201381.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"323_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S2213-2600(17)30424-1","volume":"6","author":"DB Price","year":"2018","unstructured":"Price DB, Buhl R, Chan A, et al. Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial. Lancet Respir Med. 2018;6:29\u201339.","journal-title":"Lancet Respir Med"},{"key":"323_CR38","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1164\/rccm.201503-0426OC","volume":"192","author":"RM Dunn","year":"2015","unstructured":"Dunn RM, Lehman E, Chinchilli VM, et al. Impact of age and sex on response to asthma therapy. Am J Respir Crit Care Med. 2015;192:551\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"323_CR39","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jaip.2013.07.013","volume":"1","author":"J Syk","year":"2013","unstructured":"Syk J, Malinovschi A, Johansson G, et al. Anti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial. J Allergy Clin Immunol Pract. 2013;1:639\u2013481.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"323_CR40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1164\/rccm.200411-1498OC","volume":"172","author":"AD Smith","year":"2005","unstructured":"Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med. 2005;172:453\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"323_CR41","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1016\/j.jaip.2021.03.015","volume":"9","author":"H Hao","year":"2021","unstructured":"Hao H, Bao W, Xue Y, et al. Spirometric changes in bronchodilation tests as predictors of asthma diagnosis and treatment response in patients with FEV1 >\/=80% predicted. J Allergy Clin Immunol Prac. 2021;9:3098\u20131084.","journal-title":"J Allergy Clin Immunol Prac"},{"key":"323_CR42","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1513\/AnnalsATS.202105-613OC","volume":"19","author":"JA Krishnan","year":"2022","unstructured":"Krishnan JA, Lazarus SC, Blake KV, et al. Biomarkers to predict response to inhaled corticosteroids and long-acting muscarinic antagonists in adolescents and adults with mild persistent asthma. Ann Am Thorac Soc. 2022;19:372\u201380.","journal-title":"Ann Am Thorac Soc"},{"key":"323_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01558-y","volume":"21","author":"D Singh","year":"2020","unstructured":"Singh D, Virchow JC, Canonica GW, et al. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER. Respir Res. 2020;21:285.","journal-title":"Respir Res"},{"key":"323_CR44","first-page":"1244","volume":"12","author":"L-P Boulet","year":"2024","unstructured":"Boulet L-P, Abbott C, Brusselle G, et al. Baseline characteristics and ICS\/LAMA\/LABA response in Asthma: analyses from the CAPTAIN study. the journal of allergy and clinical immunology. In Practice. 2024;12:1244\u2013538.","journal-title":"In Practice"},{"key":"323_CR45","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1056\/NEJMoa1008770","volume":"363","author":"SP Peters","year":"2010","unstructured":"Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363:1715\u201326.","journal-title":"N Engl J Med"},{"key":"323_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107334","volume":"217","author":"K Kostikas","year":"2023","unstructured":"Kostikas K, Maspero JF, Chapman KR, et al. Efficacy of mometasone\/indacaterol\/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: post hoc analysis of IRIDIUM study. Respir Med. 2023;217:107334.","journal-title":"Respir Med"},{"key":"323_CR47","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.rmed.2006.07.005","volume":"101","author":"MK Miller","year":"2007","unstructured":"Miller MK, Lee JH, Miller DP, Wenzel SE. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med. 2007;101:481\u20139.","journal-title":"Respir Med"},{"key":"323_CR48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","volume":"77","author":"S Couillard","year":"2022","unstructured":"Couillard S, Laugerud A, Jabeen M, et al. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax. 2022;77:199\u2013202.","journal-title":"Thorax"},{"key":"323_CR49","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.anai.2020.08.099","volume":"125","author":"J Oppenheimer","year":"2020","unstructured":"Oppenheimer J, Brusselle G, Busse W, et al. P202 CAPTAIN STUDY: Treatment outcomes from fluticasone furoate\/umeclidinium\/vilanterol according to history of severe asthma exacerbations. Ann Allergy Asthma Immunol. 2020;125:S26\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"323_CR50","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1183\/09031936.06.00137704","volume":"27","author":"L Jayaram","year":"2006","unstructured":"Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J. 2006;27:483.","journal-title":"Eur Respir J"},{"key":"323_CR51","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.jaci.2011.10.024","volume":"128","author":"DJ Jackson","year":"2011","unstructured":"Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol. 2011;128:1165\u201374.","journal-title":"J Allergy Clin Immunol"},{"key":"323_CR52","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00476-2020","author":"D Singh","year":"2020","unstructured":"Singh D, Virchow JC, Canonica GW, et al. Extrafine triple therapy in patients with asthma and persistent airflow limitation. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.00476-2020.","journal-title":"Eur Respir J"},{"key":"323_CR53","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1901963","volume":"380","author":"R Beasley","year":"2019","unstructured":"Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380:2020\u201330.","journal-title":"N Engl J Med"},{"key":"323_CR54","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3892\/etm.2011.268","volume":"2","author":"A Ohwada","year":"2011","unstructured":"Ohwada A, Inami K, Onuma E, Matsumoto-Yamazaki M, Atsuta R, Takahashi K. Bronchial reversibility with a short-acting \u03b22-agonist predicts the FEV1 response to administration of a long-acting \u03b22-agonist with inhaled corticosteroids in patients with bronchial asthma. Exp Ther Med. 2011;2:619\u201323.","journal-title":"Exp Ther Med"},{"key":"323_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113762","author":"E Arismendi","year":"2020","unstructured":"Arismendi E, Bantul\u00e0 M, Perpi\u00f1\u00e1 M, Picado C. Effects of obesity and asthma on lung function and airway dysanapsis in adults and children. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9113762.","journal-title":"J Clin Med"},{"key":"323_CR56","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaci.2018.02.004","volume":"141","author":"U Peters","year":"2018","unstructured":"Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol. 2018;141:1169\u201379.","journal-title":"J Allergy Clin Immunol"},{"key":"323_CR57","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1136\/thx.2007.086819","volume":"63","author":"DD Sin","year":"2008","unstructured":"Sin DD, Sutherland ER. Obesity and the lung: 4. Obesity and asthma. Thorax. 2008;63:1018\u201323.","journal-title":"Thorax"},{"key":"323_CR58","doi-asserted-by":"publisher","first-page":"AB57","DOI":"10.1016\/j.jaci.2020.12.230","volume":"147","author":"D Maselli","year":"2021","unstructured":"Maselli D, Chang S, Fowler A, et al. CAPTAIN: effects of Body Mass Index (BMI) on response to triple therapy in patients with inadequately controlled asthma on inhaled corticosteroids\/Long-acting \u03b22-agonists (ICS\/LABA). J Allergy Clin Immunol. 2021;147:AB57.","journal-title":"J Allergy Clin Immunol"},{"key":"323_CR59","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.jaci.2009.04.005","volume":"123","author":"ER Sutherland","year":"2009","unstructured":"Sutherland ER, Lehman EB, Teodorescu M, Wechsler ME. Body mass index and phenotype in subjects with mild-to-moderate persistent asthma. J Allergy Clin Immunol. 2009;123:1328\u201341.","journal-title":"J Allergy Clin Immunol"},{"key":"323_CR60","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1183\/09031936.06.00077205","volume":"27","author":"M Peters-Golden","year":"2006","unstructured":"Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006;27:495\u2013503.","journal-title":"Eur Respir J"},{"key":"323_CR61","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cea.12004","volume":"43","author":"HA Scott","year":"2013","unstructured":"Scott HA, Gibson PG, Garg ML, et al. Dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma: a randomized trial. Clin Exp Allergy. 2013;43:36\u201349.","journal-title":"Clin Exp Allergy"},{"key":"323_CR62","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2500\/aap.2016.37.3944","volume":"37","author":"T Shimoda","year":"2016","unstructured":"Shimoda T, Obase Y, Kishikawa R, Iwanaga T. Influence of cigarette smoking on airway inflammation and inhaled corticosteroid treatment in patients with asthma. Allergy Asthma Proc. 2016;37:50\u20138.","journal-title":"Allergy Asthma Proc"},{"key":"323_CR63","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/thorax.57.3.226","volume":"57","author":"GW Chalmers","year":"2002","unstructured":"Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002;57:226\u201330.","journal-title":"Thorax"},{"key":"323_CR64","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1164\/rccm.200304-503OC","volume":"168","author":"R Chaudhuri","year":"2003","unstructured":"Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 2003;168:1308\u201311.","journal-title":"Am J Respir Crit Care Med"},{"key":"323_CR65","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1136\/thx.2004.033688","volume":"60","author":"JE Tomlinson","year":"2005","unstructured":"Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 2005;60:282\u20137.","journal-title":"Thorax"},{"key":"323_CR66","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1164\/rccm.200511-1746OC","volume":"175","author":"SC Lazarus","year":"2007","unstructured":"Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007;175:783\u201390.","journal-title":"Am J Respir Crit Care Med"},{"key":"323_CR67","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/S0140-6736(17)32397-8","volume":"390","author":"A Woodcock","year":"2017","unstructured":"Woodcock A, Vestbo J, Bakerly ND, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017;390:2247\u201355.","journal-title":"Lancet"},{"key":"323_CR68","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jaci.2007.07.016","volume":"120","author":"SE Pedersen","year":"2007","unstructured":"Pedersen SE, Bateman ED, Bousquet J, et al. Determinants of response to fluticasone propionate and salmeterol\/fluticasone propionate combination in the gaining optimal asthma control study. J Allergy Clin Immunol. 2007;120:1036\u201342.","journal-title":"J Allergy Clin Immunol"},{"key":"323_CR69","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.rmed.2011.02.011","volume":"105","author":"J Haughney","year":"2011","unstructured":"Haughney J, Aubier M, J\u00f8rgensen L, et al. Comparing asthma treatment in elderly versus younger patients. Respir Med. 2011;105:838\u201345.","journal-title":"Respir Med"},{"key":"323_CR70","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1016\/j.jaip.2020.04.013","volume":"8","author":"DE Doherty","year":"2020","unstructured":"Doherty DE, Bleecker ER, Moroni-Zentgraf P, Zaremba-Pechmann L, Kerstjens HAM. Tiotropium respimat efficacy and safety in asthma: relationship to age. J Allergy Clin Immunol Pract. 2020;8:2653\u2013604.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"323_CR71","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0067-2021","author":"NU Chowdhury","year":"2021","unstructured":"Chowdhury NU, Guntur VP, Newcomb DC, Wechsler ME. Sex and gender in asthma. Eur Respir Rev. 2021. https:\/\/doi.org\/10.1183\/16000617.0067-2021.","journal-title":"Eur Respir Rev"},{"key":"323_CR72","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/ACI.0b013e3283292207","volume":"9","author":"E Forno","year":"2009","unstructured":"Forno E, Celedon JC. Asthma and ethnic minorities: socioeconomic status and beyond. Curr Opin Allergy Clin Immunol. 2009;9:154\u201360.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"323_CR73","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S2213-2600(16)30048-0","volume":"4","author":"MC Peters","year":"2016","unstructured":"Peters MC, McGrath KW, Hawkins GA, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med. 2016;4:574\u201384.","journal-title":"Lancet Respir Med"},{"key":"323_CR74","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S2213-2600(20)30053-9","volume":"8","author":"ID Pavord","year":"2020","unstructured":"Pavord ID, Holliday M, Reddel HK, et al. Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. Lancet Respir Med. 2020;8:671\u201380.","journal-title":"Lancet Respir Med"},{"key":"323_CR75","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1056\/NEJMoa2118813","volume":"386","author":"E Israel","year":"2022","unstructured":"Israel E, Cardet JC, Carroll JK, et al. Reliever-triggered inhaled glucocorticoid in Black and Latinx adults with asthma. N Engl J Med. 2022;386:1505\u201318.","journal-title":"N Engl J Med"},{"key":"323_CR76","first-page":"1487","volume":"58","author":"A Papi","year":"2021","unstructured":"Papi A, Barnes N, Fowler A, et al. CAPTAIN: Effects of lung function at screening (FEV1 % predicted) as a continuous variable on treatment outcomes. Eur Respir J. 2021;58:1487.","journal-title":"Eur Respir J"},{"key":"323_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107172","volume":"211","author":"RN Van Zyl-Smit","year":"2023","unstructured":"Van Zyl-Smit RN, Kerstjens HA, Maspero JF, et al. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone\/indacaterol\/glycopyrronium in patients with asthma with or without persistent airflow limitation: post hoc analysis from the IRIDIUM study. Respir Med. 2023;211:107172.","journal-title":"Respir Med"},{"key":"323_CR78","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa2203163","volume":"386","author":"A Papi","year":"2022","unstructured":"Papi A, Chipps BE, Beasley R, et al. Albuterol-budesonide fixed-dose combination rescue inhaler for asthma. N Engl J Med. 2022;386:2071\u201383.","journal-title":"N Engl J Med"},{"key":"323_CR79","doi-asserted-by":"crossref","unstructured":"Boulet L, Lee L, Kerstjens H, et al., editors. CAPTAIN: Effects of age on response to triple therapy in patients with inadequately controlled asthma on ICS\/LABA. Poster presented at European Respiratory Society 2021; 2020; https:\/\/www.ersnet.org\/congress-and-events\/congress\/.","DOI":"10.1183\/13993003.congress-2020.2631"},{"key":"323_CR80","doi-asserted-by":"crossref","unstructured":"Kerstjens HA, Lawrence D, Mezzi K, Brittain D, Jaumont X, Chapman KR, editors. Effect of once daily (o.d.) mometasone\/indacaterol\/glycopyrronium (MF\/IND\/GLY) vs o.d. MF\/IND and twice daily (b.i.d.) fluticasone\/salmeterol (FLU\/SAL) with respect to age, age at asthma-onset and BMI at baseline: Subgroup analysis from IRIDIUM study. Poster presented at European Respiratory Society 2022; 2022; Barcelona.","DOI":"10.1183\/13993003.congress-2022.1638"},{"key":"323_CR81","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.rmed.2012.01.010","volume":"106","author":"G Brusselle","year":"2012","unstructured":"Brusselle G, Pech\u00e9 R, Van den Brande P, Verhulst A, Hollanders W, Bruhwyler J. Real-life effectiveness of extrafine beclometasone dipropionate\/formoterol in adults with persistent asthma according to smoking status. Respir Med. 2012;106:811\u20139.","journal-title":"Respir Med"},{"key":"323_CR82","doi-asserted-by":"crossref","unstructured":"Papi A, Lee L, Kerstjens H, et al., editors. CAPTAIN: Effects of smoking status on response to triple therapy in patients with inadequately controlled asthma on ICS\/LABA. Poster presented at European Respiratory Society 2020; 2020.","DOI":"10.1183\/13993003.congress-2020.2272"},{"key":"323_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12145","volume":"12","author":"A Papi","year":"2022","unstructured":"Papi A, Singh D, Virchow JC, Canonica GW, Vele A, Georges G. Normalisation of airflow limitation in asthma: post-hoc analyses of TRIMARAN and TRIGGER. Clin Transl Allergy. 2022;12:e12145.","journal-title":"Clin Transl Allergy"},{"key":"323_CR84","first-page":"61","volume":"133","author":"J Hardy","year":"2020","unstructured":"Hardy J, Tewhaiti-Smith J, Baggott C, et al. Combination budesonide\/formoterol inhaler as sole reliever therapy in M\u0101ori and Pacific people with mild and moderate asthma. N Z Med J. 2020;133:61\u201372.","journal-title":"N Z Med J"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00323-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-025-00323-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00323-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:04:46Z","timestamp":1773673486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-025-00323-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["323"],"URL":"https:\/\/doi.org\/10.1007\/s41030-025-00323-0","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Guy Brusselle has received speaker fees from and served on advisory boards for AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, MSD, Novartis, and Sanofi. Peter G. Gibson has received speaker\u2019s fees, and research grants from AstraZeneca, Chiesi, GSK, and Novartis. John J. Oppenheimer has served on adjudication committees or data and safety monitoring boards for AstraZeneca, GSK, Novartis, and Sanofi\/Regeneron, and has received grants and personal fees from GSK. Ian D. Pavord has received speaker\u2019s honoraria for speaking at sponsored meetings from AstraZeneca, Aerocrine, Almirall, Sanofi\/Regeneron, Menarini, and GSK, and payments for organizing educational events from AstraZeneca, GSK, and Sanofi\/Regeneron. He has received honoraria for attending advisory panels with Sanofi\/Regeneron, AstraZeneca, GSK, Merck, Circassia, Chiesi, and Areteia. He has received sponsorship to attend international scientific meetings from GSK, AstraZeneca, and Sanofi\/Regeneron. David Leather and Emilio Pizzichini are former employees of GSK and David Leather holds financial equities in GSK. Jodie Crawford, Alison Moore, and Marcus Stanaland are employees of GSK and hold financial equities in GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not required as this article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}